Population Pharmacokinetics of Finafloxacin in Healthy Volunteers and Patients with Complicated Urinary Tract Infections

被引:0
|
作者
Taubert, Max [1 ]
Lueckermann, Mark [2 ]
Vente, Andreas [2 ]
Dalhoff, Axel [3 ]
Fuhr, Uwe [1 ]
机构
[1] Univ Hosp Cologne, Clin Pharmacol Unit, Dept Pharmacol, Cologne, Germany
[2] MerLion Pharmaceut GmbH, Berlin, Germany
[3] Christian Albrechts Univ Kiel, Inst Infect Med, Kiel, Germany
关键词
clinical trials; finafloxacin; pharmacodynamics; population pharmacokinetics; urinary tract infection; ECONOMIC-EVALUATION; INVITRO ACTIVITY; FLUOROQUINOLONE; CIPROFLOXACIN; THERAPY; PH; ACETAMINOPHEN; COMPLETENESS; ASPIRIN; HEIGHT;
D O I
10.1128/AAC.02328-17
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Finafloxacin is a novel fluoroquinolone with increased antibacterial activity at acidic pH and reduced susceptibility to several resistance mechanisms. A phase II study revealed a good efficacy/safety profile in patients with complicated urinary tract infections (cUTIs), while the pharmacokinetics was characterized by highly variable concentration-versus-time profiles, suggesting the need for an elaborated pharmacokinetic model. Data from three clinical trials were evaluated: 127 healthy volunteers were dosed orally (n = 77) or intravenously (n = 50), and 139 patients with cUTI received finafloxacin intravenously. Plasma (2,824 samples from volunteers and 414 samples from patients) and urine (496 samples from volunteers and 135 samples patients) concentrations were quantified by liquid chromatography-tandem mass spectrometry (LC-MS/MS). NONMEM was used to build a population pharmacokinetic model, and pharmacokinetic/pharmacodynamic relationships were investigated via simulations and logistic regression. A two-compartment model with first-order elimination described the data best (central volume of distribution [V-c] and peripheral volume of distribution [V-p] of 47 liters [20%] and 43 liters [67%], respectively, and elimination clearance and intercompartmental clearance of 21 liters/h [54%] and 2.8 liters/h [57%], respectively [median bootstrap estimates {coefficients of variation}]). V-c increased with body surface area, and clearance was reduced in patients (-29%). Oral absorption was described best by parallel first-and zero-order processes (bioavailability of 75%). No pharmacodynamic surrogate parameter of clinical/microbiological outcome could be identified, which depended exclusively on the MIC of the causative pathogens. Despite the interindividual variability, the present data set does not support covariate-based dose adjustments. Based on the favorable safety and efficacy data, the clinical relevance of the observed variability appears to be limited.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Population pharmacokinetics of finafloxacin in healthy volunteers and patients suffering from urinary tract infections
    Taubert, M.
    Lueckermann, M.
    Fuhr, U.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 : S16 - S16
  • [2] Pharmacokinetics of Intravenous Finafloxacin in Healthy Volunteers
    Taubert, Max
    Chiesa, Joseph
    Lueckermann, Mark
    Fischer, Carsten
    Dalhoff, Axel
    Fuhr, Uwe
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2017, 61 (10)
  • [3] Finafloxacin for the treatment of urinary tract infections
    Bartoletti, Riccardo
    Cai, Tommaso
    Perletti, Giampaolo
    Wagenlehner, Florian M. E.
    Johansen, Truls E. Bjerklund
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2015, 24 (07) : 957 - 963
  • [4] CEFTAZIDIME - PHARMACOKINETICS IN YOUNG VOLUNTEERS VERSUS ELDERLY PATIENTS AND THERAPEUTIC EFFICACY WITH COMPLICATED URINARY-TRACT INFECTIONS
    NABER, KG
    KEES, F
    GROBECKER, H
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1983, 12 : 41 - 45
  • [5] Pharmacokinetics of ertapenem in outpatients with complicated urinary tract infections
    Zhou, Jian
    Sulaiman, Zuraidah
    Llorin, Ryan M.
    Hee, Kim-Hor
    Lee, Lawrence Soon-U
    Lye, David C.
    Fisher, Dale A.
    Tam, Vincent H.
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (09) : 2517 - 2521
  • [6] Urinary Pharmacokinetics and Bactericidal Activity of Finafloxacin (200 and 800 mg) in Healthy Volunteers Receiving a Single Oral Dose
    Wagenlehner, Florian M. E.
    Wagenlehner, Christine M.
    Blenk, Birgit
    Blenk, Holger
    Schubert, Sabine
    Dalhoff, Axel
    Naber, Kurt G.
    [J]. CHEMOTHERAPY, 2011, 57 (02) : 97 - 107
  • [7] Complicated urinary tract infections
    Kranz, J.
    Wagenlehner, F. M. E.
    Schneidewind, L.
    [J]. UROLOGE, 2020, 59 (12): : 1480 - 1485
  • [8] Complicated urinary tract infections
    Melekos, MD
    Naber, KG
    [J]. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2000, 15 (04) : 247 - 256
  • [9] Complicated urinary tract infections
    Lichtenberger P.
    Hooton T.M.
    [J]. Current Infectious Disease Reports, 2008, 10 (6) : 499 - 504
  • [10] Population pharmacokinetics of clinafloxacin in healthy volunteers and patients with infections - Experience with heterogeneous pharmacokinetic data
    Frame, B
    Koup, J
    Miller, R
    Lalonde, R
    [J]. CLINICAL PHARMACOKINETICS, 2001, 40 (04) : 307 - 315